ORALLY ACTIVE MANNOSIDES SUBVERT ANTIBIOTIC RESISTANCE IF E COLI IN BLADDER

如果膀胱中有大肠杆菌，口服活性甘露糖苷可消除抗生素耐药性

• 批准号: 8361464
• 负责人: SCOTT J. HULTGREN
• 金额: $ 1.24万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-01-01 至 2011-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8361464
• 关键词: Antibiotic Resistance; Bladder; Escherichia coli; Funding; Grant; Health; Mannosides; Mass Spectrum Analysis; Multi-Drug Resistance; National Center for Research Resources; Principal Investigator; Research; Research Infrastructure; Resistance to infection; Resources; Source; Trimethoprim-Sulfamethoxazole; United States National Institutes of Health; Urinary tract infection; Uropathogen; antimicrobial; biomedical resource; cost; pathogen

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Proliferation of antibiotic-resistant pathogens has been described as an impending health crisis1. This is increasingly evident for urinary tract infections (UTI) where resistance to first-line empiric therapy with trimethoprim-sulfamethoxazole (TMP-SMZ) by uropathogens complicates treatment, and drives use of alternate antimicrobial agents2. As a consequence, multidrug-resistant uropathogens are on the rise, making the straightforward treatment of UTI increasingly difficult.

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 抗药性病原体的扩散已被描述为一个迫在眉睫的健康危机1。这在尿路感染（UTI）中越来越明显，其中尿路病原体对甲氧苄啶-磺胺甲恶唑（TMP-SMZ）一线经验性治疗的耐药性使治疗复杂化，并促使使用替代抗菌药物2。 因此，多药耐药尿路病原体正在上升，使UTI的直接治疗变得越来越困难。